ClinicalTrials.gg
CompletedNCT05455684VENTURA-1Updated Nov 6, 2025Results posted

A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy

A Phase 3 interventional study of Aticaprant and Placebo in Depressive Disorder, Major and Anhedonia, sponsored by Janssen Research & Development, LLC. Completed at 120 sites in 13 countries. Open to participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2025-11-06.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
513
Allocation
Randomized
Ages
18 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 59 studies in Depressive Disorder, Major by Johnson & Johnson — 5 open to participants now, 5 under way, 5 of them phase 3. Depressive Disorder, Major · Johnson & Johnson.

Enrollment
10th of 52
513 · median 203
Started
2022
with 2 others
Phase 3
23 of 59
5 open now
Registered
47th of 59
by date

Among the 59 studies in Depressive Disorder, Major by Johnson & Johnson, this one is the 10th largest by enrollment of the 52 interventional ones that give a count, is one of 3 that started in 2022, is one of 23 in phase 3, and was the 47th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

5 of the 59 studies in Depressive Disorder, Major by Johnson & Johnson are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 413 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 74 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Depressive Disorder, Major by Johnson & Johnson, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy of aticaprant compared with placebo as adjunctive therapy to an antidepressant in improving depressive symptoms in adult participants with major depressive disorder (MDD) with moderate-to-severe anhedonia (ANH+) who have had an inadequate response to current antidepressant therapy with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI).

Read the detailed description

Depression is a common and serious psychiatric disorder which is a leading cause of disability worldwide and is associated with elevated mortality and suicide risk. Aticaprant (JNJ-67953964) is a once daily, highly selective kappa opioid receptor (KOR) antagonist, with demonstrated selectivity over mu opioid receptor (MOR) and delta opioid receptor (DOR) being developed for adjunctive treatment of major depressive disorder (MDD) with moderate-to-severe anhedonia (ANH+). The study consists of a screening phase (up to 30 days prior to randomization), double-blind treatment phase (43 days), and follow-up phase (up to 14 days). The total duration of the study will be up to 87 days. Safety evaluations including adverse events, physical examinations, urine drug test, alcohol breath tests, and clinical laboratory tests will be assessed at specific time points during this study.

03

Conditions studied

  • Depressive Disorder, Major
  • Anhedonia
04

Who can participate

Ages eligible
18 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be medically stable on the basis of physical examination, medical history, vital signs, and 12-lead (ECG) performed at screening and baseline
  • Have a Hamilton Depression Rating Scale 17 item (HDRS-17) total score of 20 or higher at the first and second screening interviews and must not demonstrate a improvement between the first and the second independent HDRS-17 assessments
  • Meet -5th edition (DSM-5) diagnostic criteria for recurrent or single episode major depressive disorder (MDD), without psychotic features, based upon clinical assessment and confirmed by the structured clinical interview for DSM-5 Axis I disorders-clinical trials version (SCID-CT). Participants 65 years of age or older must have had the first onset of depression prior to 55 years of age
  • Have had an inadequate response to at least 1 oral antidepressant treatment, administered at an adequate dose (at or above the minimum therapeutic dose per Massachusetts General Hospital Antidepressant Treatment Response Questionnaire [MGH ATRQ]) and duration (at least 6 weeks) in the current episode of depression. An inadequate response is defined as less than(\<) 50% reduction in depressive symptom severity but with some improvement (>0%) (ie, there may be minimal to moderate symptomatic improvement since the initiation of treatment, but some of the initial symptoms are still present, troubling to the participant and affecting behavior and function), as assessed by the MGH ATRQ
  • Is currently receiving and tolerating well any one of the following selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) for depressive symptoms at screening, in any approved formulation and available in the participating country/territory: citalopram, duloxetine, escitalopram, fluvoxamine, fluoxetine, milnacipran, levomilnacipran, paroxetine, sertraline, venlafaxine, desvenlafaxine at a stable dose for at least 6 weeks. The current antidepressant cannot be the first antidepressant treatment for the first lifetime episode of depression
  • Participant's current major depressive episode, and antidepressant treatment response in the current depressive episode, must all be confirmed by the site independent qualification assessment

Exclusion criteria

Exclusion Criteria:

  • Have had in the current depressive episode, no response (treatment failure) to 5 or more antidepressant treatments including the current SSRI/SNRI (that is, the one presumed to be continued in the treatment phase) assessed using the Massachusetts General Hospital Antidepressant Treatment Response Questionnaire (MGH ATRQ)
  • Has a history or evidence of noncompliance with current antidepressant therapy
  • Has a history of moderate-to-severe substance use disorder including alcohol use disorder according to criteria within 6 months before screening
  • Has had in the current episode an inadequate response to adequate course of intravenous or intranasal ketamine or esketamine, electroconvulsive therapy, vagal nerve stimulation, or deep brain stimulation device
  • Has current, or a history (past 6 months), of seizures
  • Has a current homicidal ideation/intent, per the investigator's clinical judgment, or has suicidal ideation with some intent to act within 3 months prior to the start of the Screening Phase, per the investigator's clinical judgment or based on the Columbia Suicide Severity Rating Scale (C-SSRS), corresponding to a response of "Yes" on Item 4 or Item 5, or a history of suicidal behavior within the past 6 months prior to the start of the Screening Phase. Participants reporting suicidal ideation with intent to act or suicidal behavior at baseline should be excluded
  • Has one or more of the following diagnoses: a) A DSM-5 diagnosis (which has been the primary focus of psychiatric treatment within the past 2 years) of any of the following: panic disorder, generalized anxiety disorder, social anxiety disorder, specific phobia; b) A current (in the past year) DSM-5 diagnosis of: obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), anorexia nervosa, bulimia nervosa; c) A current or prior (lifetime) DSM-5 diagnosis of: a psychotic disorder or MDD with psychotic features, bipolar or related disorders, intellectual disability, autism spectrum disorder, borderline personality disorder, antisocial personality disorder, histrionic personality disorder, narcissistic personality disorders, somatoform disorders
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
513 participants (actual)

Study arms

  • Experimental
    Aticaprant

    Participants will receive aticaprant tablets orally once daily for 42 days during double-blind treatment phase in addition to the current antidepressant selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor (SSRI/SNRI) therapy. Participants who will complete the double-blind treatment phase (Day 43) may be eligible to participate in a separate 52-week open-label long-term safety study (67953964MDD3003).

    Drug: Aticaprant

  • Placebo comparator
    Placebo

    Participants will receive matching placebo orally once daily for 42 days during double-blind treatment phase in addition to their current antidepressant (SSRI/SNRI) therapy. Participants who will complete the double-blind treatment phase (Day 43) may be eligible to participate in a separate 52-week open-label long-term safety study (67953964MDD3003).

    Other: Placebo

Interventions

  • Aticaprant will be administered orally as tablets.

    Also known as: JNJ-67953964

  • OtherPlacebo

    Placebo will be administered orally as tablets.

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Day 43 in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score

    The MADRS is a clinician-rated scale designed to measure depression severity and detect changes due to antidepressant treatment. The scale consists of 10 items (apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score is the sum of scores from individual question items, which ranges from 0 to 60; higher scores represent a more severe condition. Negative change in MADRS total score indicates improvement.

    Time frame: Baseline (Day 1) to Day 43

Secondary outcomes

  1. Change From Baseline to Day 43 in Dimensional Anhedonia Rating Scale (DARS) Total Score

    The DARS is a 17-item self-report questionnaire that is designed to assess anhedonia in MDD across the 4 domains: hobbies, social activities, food/drink, and sensory experience. The DARS scale measures desire, motivation, effort, and consummatory pleasure. The DARS is rated on a 5-point Likert scale (0=not at all, 1=slightly, 2=moderately, 3=mostly, 4=very much) and responses are summed to generate the total score (ranges from 0 to 68). A lower total score is indicative of greater anhedonia. Positive changes in DARS total score indicate improvement.

    Time frame: Baseline (Day 1) to Day 43

  2. Change From Baseline Over Time in MADRS Total Score

    Change from baseline over time in MADRS total score is reported. The MADRS is a clinician-rated scale designed to measure depression severity and detect changes due to antidepressant treatment. The scale consists of 10 items (apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score is the sum of scores from individual question items, which ranges from 0 to 60; higher scores represent a more severe condition. Negative change in MADRS total score indicates improvement.

    Time frame: Baseline (Day 1), Days 15, 29 and 43

  3. Percentage of Participants Who Achieved Response on Depressive Symptoms Scale Based on MADRS Total Score at Day 43

    Percentage of participants who achieved response on depressive symptoms scale based on MADRS total score at Day 43 are reported. Responders are defined as participants with a \>=50 percent (%) improvement in the MADRS total score from baseline to a given timepoint. The MADRS is a clinician-rated scale designed to measure depression severity and detect changes due to antidepressant treatment. The scale consists of 10 items (apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score is the sum of scores from individual question items, which ranges from 0 to 60; higher scores represent a more severe condition.

    Time frame: At Day 43

  4. Percentage of Participants With Remission of Depressive Symptoms Based on MADRS Total Score at Day 43

    Percentage of participants with remission of depressive symptoms based on MADRS total score at Day 43 is reported. Participant is defined as a remitter at a given time point if the MADRS total score is less than or equal to (\<=)10 at that time point. The MADRS is a clinician-rated scale designed to measure depression severity and detect changes due to antidepressant treatment. The scale consists of 10 items (apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score is the sum of scores from individual question items, which ranges from 0 to 60; higher scores represent a more severe condition.

    Time frame: At Day 43

  5. Change From Baseline to Day 43 in Patient Health Questionnaire, 9-Item (PHQ-9) Total Score

    Change from baseline to Day 43 in PHQ-9 total score is reported. The PHQ-9 is a 9-item, participant reported outcome measure to assess depressive symptoms. The scale scores each of the 9 symptom domains of the Diagnostic and Statistical Manual of Mental Disorders-5th Edition (DSM-5) MDD criteria. Each item is rated on a 4 point scale (0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day). The participant's item responses are summed to provide a total score (range of 0 to 27), with higher scores indicating greater severity of depressive symptoms. The severity of the PHQ-9 is categorized as follows: none-minimal (0-4), mild (5-9), moderate (10-14), moderately severe (15-19) and severe (20-27). Negative changes in PHQ-9 total score indicate improvement.

    Time frame: Baseline (Day 1) to Day 43

  6. Change From Baseline Over Time in DARS Total Score

    Change from baseline over time in DARS total score is reported. The DARS is a 17-item self-report questionnaire that is designed to assess anhedonia in MDD across the 4 domains: hobbies, social activities, food/drink, and sensory experience. The DARS scale measures desire, motivation, effort, and consummatory pleasure. The DARS is rated on a 5-point Likert scale (0=not at all, 1=slightly, 2=moderately, 3=mostly, 4=very much) and responses are summed to generate the total score (range of 0 to 68). A lower total score is indicative of greater anhedonia. Positive changes in DARS total score indicate improvement.

    Time frame: Baseline (Day 1), Days 15, 29, and 43

  7. Change From Baseline Over Time in the PHQ-9 Anhedonia-specific Item (PHQ-9, Item 1)

    Change from baseline over time in the PHQ-9 anhedonia-specific item (PHQ-9, item 1 is little interest or pleasure in doing things) is reported. The PHQ-9 is a 9-item, participant reported outcome measure to assess depressive symptoms. The scale scores each of the 9 symptom domains of the Diagnostic and Statistical Manual of Mental Disorders-5th Edition (DSM-5) MDD criteria. Each item is rated on a 4 point scale (0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day). The participant's item responses are summed to provide a total score (range of 0 to 27), with higher scores indicating greater severity of depressive symptoms. The severity of the PHQ-9 is categorized as follows: none-minimal (0-4), mild (5-9), moderate (10-14), moderately severe (15-19) and severe (20-27). Negative changes in PHQ-9 total score indicate improvement.

    Time frame: Baseline (Day 1), Day 15, Day 29, and Day 43

  8. Percentage of Participants With a Score Less Than (<) 2 in the PHQ-9 Anhedonia-specific Item (PHQ-9, Item 1) at Day 43

    Percentage of participants with a score \<2 in the PHQ-9 anhedonia-specific item (PHQ-9, item 1 is little interest or pleasure in doing things) at Day 43 is reported. The PHQ-9 is a 9-item, participant reported outcome measure to assess depressive symptoms. The scale scores each of the 9 symptom domains of the Diagnostic and Statistical Manual of Mental Disorders-5th Edition (DSM-5) MDD criteria. Each item is rated on a 4 point scale (0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day). The participant's item responses are summed to provide a total score (range of 0 to 27), with higher scores indicating greater severity of depressive symptoms. The severity of the PHQ-9 is categorized as follows: none-minimal (0-4), mild (5-9), moderate (10-14), moderately severe (15-19) and severe (20-27).

    Time frame: At Day 43

  9. Change From Baseline Over Time in Patient Reported Outcomes Measurement Information System Short Form - Ability to Participate in Social Roles and Activities - 8a (PROMIS-APS 8a)

    Change from baseline over time in the PROMIS-APS 8a is reported. This 8-item measure assesses participants' ability to participate in social roles and activities. The items measures the degree of involvement in social roles, activities, and responsibilities, including work, family, friends, and leisure. Each item is rated on a 5-point ordinal scale including 1=always, 2=usually, 3=sometimes, 4=rarely and 5=never, with higher scores indicating better social functioning. The total scores of PROMIS-APS 8a ranges from 8 to 40 and is transformed using a T-score metric with a mean of 50 and a standard deviation of 10. T-score ranges from 25.9 to 65.4, a higher score indicates better social functioning. Positive change in score indicates improvement.

    Time frame: Baseline (Day 1), Days 15, 29, and 43

  10. Percent Change From Baseline Over Time in Work Productivity and Activity Impairment: Depression (WPAI:D)

    The WPAI:D questionnaire is a validated short instrument that assesses impairment in work and other regular activities over the past 7 days. The WPAI yields four types of scores: (a) Absenteeism (work time missed); (b) Presenteeism (impairment at work / reduced on-the-job effectiveness); (c) Work productivity loss (overall work impairment / absenteeism plus presenteeism); (d) Activity Impairment. The first three scores are derived only for respondents who were working (should be missing for non-working), but the last score is applicable for all respondents. Each score ranges from 0 to 100 with higher scores indicating greater impairment and less productivity. Negative changes in score indicates less impairment and greater productivity.

    Time frame: Baseline (Day 1), Days 29 and 43

  11. DB Treatment Phase: Percentage of Participants With Treatment Emergent Adverse Events (TEAEs)

    Percentage of participants with TEAEs during DB treatment phase are reported. A TEAE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. A TEAE does not necessarily have a causal relationship with the intervention. TEAEs included both serious and non serious adverse events. TEAEs were defined as AEs with onset during the DB Treatment Phase, or AEs that are a consequence of a pre-existing condition that has worsened since baseline (Day 1).

    Time frame: From start of treatment (Day 1) up to Day 43

  12. Follow-up (FU) Phase: Percentage of Participants With AEs

    An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention.

    Time frame: From Day 44 up to Day 57

07

Results

Posted Nov 6, 2025

Participant flow

Participant flow — Overall Study
MilestonePlaceboAticaprant 10 mg
Started259254
Safety analysis set258253
Participants who entered follow-up phase2414
Completed244240
Not completed1514
Withdrew: Withdrawal by subject74
Withdrew: Lost to follow-up33
Withdrew: Adverse event23
Withdrew: Protocol violation11
Withdrew: Non-compliant with study drug01
Withdrew: Other12
Withdrew: Randomized but not treated10

Outcome measures

PrimaryChange From Baseline to Day 43 in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score

The MADRS is a clinician-rated scale designed to measure depression severity and detect changes due to antidepressant treatment. The scale consists of 10 items (apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score is the sum of scores from individual question items, which ranges from 0 to 60; higher scores represent a more severe condition. Negative change in MADRS total score indicates improvement.

Time frame:
Baseline (Day 1) to Day 43
Reported as:
Least squares mean · Units on a scale
Change From Baseline to Day 43 in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
Units on a scalePlaceboAticaprant 10 mg
Change From Baseline to Day 43 in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score-11.4 ± 0.98-12.3 ± 0.95
Statistical analysis
  • Placebo vs Aticaprant 10 mg · Mixed Model for Repeated Measures · p = =0.467 · Least square mean difference: -0.9 · 95% CI -3.24 to 1.49
SecondaryChange From Baseline to Day 43 in Dimensional Anhedonia Rating Scale (DARS) Total Score

The DARS is a 17-item self-report questionnaire that is designed to assess anhedonia in MDD across the 4 domains: hobbies, social activities, food/drink, and sensory experience. The DARS scale measures desire, motivation, effort, and consummatory pleasure. The DARS is rated on a 5-point Likert scale (0=not at all, 1=slightly, 2=moderately, 3=mostly, 4=very much) and responses are summed to generate the total score (ranges from 0 to 68). A lower total score is indicative of greater anhedonia. Positive changes in DARS total score indicate improvement.

Time frame:
Baseline (Day 1) to Day 43
Reported as:
Least squares mean · Units on a scale
Change From Baseline to Day 43 in Dimensional Anhedonia Rating Scale (DARS) Total Score
Units on a scalePlaceboAticaprant 10 mg
Change From Baseline to Day 43 in Dimensional Anhedonia Rating Scale (DARS) Total Score10.5 ± 1.5012.0 ± 1.43
SecondaryChange From Baseline Over Time in MADRS Total Score

Change from baseline over time in MADRS total score is reported. The MADRS is a clinician-rated scale designed to measure depression severity and detect changes due to antidepressant treatment. The scale consists of 10 items (apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score is the sum of scores from individual question items, which ranges from 0 to 60; higher scores represent a more severe condition. Negative change in MADRS total score indicates improvement.

Time frame:
Baseline (Day 1), Days 15, 29 and 43
Reported as:
Least squares mean · Units on a scale
Change From Baseline Over Time in MADRS Total Score
Units on a scalePlaceboAticaprant 10 mg
At Day 15-5.4 ± 0.76-6.6 ± 0.72
At Day 29-9.4 ± 0.90-11.1 ± 0.87
At Day 43-11.4 ± 0.98-12.3 ± 0.95
SecondaryPercentage of Participants Who Achieved Response on Depressive Symptoms Scale Based on MADRS Total Score at Day 43

Percentage of participants who achieved response on depressive symptoms scale based on MADRS total score at Day 43 are reported. Responders are defined as participants with a \>=50 percent (%) improvement in the MADRS total score from baseline to a given timepoint. The MADRS is a clinician-rated scale designed to measure depression severity and detect changes due to antidepressant treatment. The scale consists of 10 items (apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score is the sum of scores from individual question items, which ranges from 0 to 60; higher scores represent a more severe condition.

Time frame:
At Day 43
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved Response on Depressive Symptoms Scale Based on MADRS Total Score at Day 43
Percentage of participantsPlaceboAticaprant 10 mg
Percentage of Participants Who Achieved Response on Depressive Symptoms Scale Based on MADRS Total Score at Day 4322.829.4
SecondaryPercentage of Participants With Remission of Depressive Symptoms Based on MADRS Total Score at Day 43

Percentage of participants with remission of depressive symptoms based on MADRS total score at Day 43 is reported. Participant is defined as a remitter at a given time point if the MADRS total score is less than or equal to (\<=)10 at that time point. The MADRS is a clinician-rated scale designed to measure depression severity and detect changes due to antidepressant treatment. The scale consists of 10 items (apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score is the sum of scores from individual question items, which ranges from 0 to 60; higher scores represent a more severe condition.

Time frame:
At Day 43
Reported as:
Number · Percentage of participants
Percentage of Participants With Remission of Depressive Symptoms Based on MADRS Total Score at Day 43
Percentage of participantsPlaceboAticaprant 10 mg
Percentage of Participants With Remission of Depressive Symptoms Based on MADRS Total Score at Day 4312.617.6
SecondaryChange From Baseline to Day 43 in Patient Health Questionnaire, 9-Item (PHQ-9) Total Score

Change from baseline to Day 43 in PHQ-9 total score is reported. The PHQ-9 is a 9-item, participant reported outcome measure to assess depressive symptoms. The scale scores each of the 9 symptom domains of the Diagnostic and Statistical Manual of Mental Disorders-5th Edition (DSM-5) MDD criteria. Each item is rated on a 4 point scale (0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day). The participant's item responses are summed to provide a total score (range of 0 to 27), with higher scores indicating greater severity of depressive symptoms. The severity of the PHQ-9 is categorized as follows: none-minimal (0-4), mild (5-9), moderate (10-14), moderately severe (15-19) and severe (20-27). Negative changes in PHQ-9 total score indicate improvement.

Time frame:
Baseline (Day 1) to Day 43
Reported as:
Least squares mean · Units on a scale
Change From Baseline to Day 43 in Patient Health Questionnaire, 9-Item (PHQ-9) Total Score
Units on a scalePlaceboAticaprant 10 mg
Change From Baseline to Day 43 in Patient Health Questionnaire, 9-Item (PHQ-9) Total Score-5.9 ± 0.58-6.7 ± 0.55
Statistical analysis
  • Placebo vs Aticaprant 10 mg · Least square mean difference: -0.8 · 95% CI -2.21 to 0.52
SecondaryChange From Baseline Over Time in DARS Total Score

Change from baseline over time in DARS total score is reported. The DARS is a 17-item self-report questionnaire that is designed to assess anhedonia in MDD across the 4 domains: hobbies, social activities, food/drink, and sensory experience. The DARS scale measures desire, motivation, effort, and consummatory pleasure. The DARS is rated on a 5-point Likert scale (0=not at all, 1=slightly, 2=moderately, 3=mostly, 4=very much) and responses are summed to generate the total score (range of 0 to 68). A lower total score is indicative of greater anhedonia. Positive changes in DARS total score indicate improvement.

Time frame:
Baseline (Day 1), Days 15, 29, and 43
Reported as:
Least squares mean · Units on a scale
Change From Baseline Over Time in DARS Total Score
Units on a scalePlaceboAticaprant 10 mg
At Day 154.8 ± 1.225.9 ± 1.20
At Day 298.3 ± 1.3810.0 ± 1.32
At Day 4310.5 ± 1.5012.0 ± 1.43
SecondaryChange From Baseline Over Time in the PHQ-9 Anhedonia-specific Item (PHQ-9, Item 1)

Change from baseline over time in the PHQ-9 anhedonia-specific item (PHQ-9, item 1 is little interest or pleasure in doing things) is reported. The PHQ-9 is a 9-item, participant reported outcome measure to assess depressive symptoms. The scale scores each of the 9 symptom domains of the Diagnostic and Statistical Manual of Mental Disorders-5th Edition (DSM-5) MDD criteria. Each item is rated on a 4 point scale (0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day). The participant's item responses are summed to provide a total score (range of 0 to 27), with higher scores indicating greater severity of depressive symptoms. The severity of the PHQ-9 is categorized as follows: none-minimal (0-4), mild (5-9), moderate (10-14), moderately severe (15-19) and severe (20-27). Negative changes in PHQ-9 total score indicate improvement.

Time frame:
Baseline (Day 1), Day 15, Day 29, and Day 43
Reported as:
Mean · Units on a scale
Change From Baseline Over Time in the PHQ-9 Anhedonia-specific Item (PHQ-9, Item 1)
Units on a scalePlaceboAticaprant 10 mg
At Day 15-0.4 ± 1.04-0.5 ± 1.07
At Day 29-0.5 ± 1.04-0.8 ± 1.05
At Day 43-0.7 ± 1.09-1.0 ± 1.09
SecondaryPercentage of Participants With a Score Less Than (<) 2 in the PHQ-9 Anhedonia-specific Item (PHQ-9, Item 1) at Day 43

Percentage of participants with a score \<2 in the PHQ-9 anhedonia-specific item (PHQ-9, item 1 is little interest or pleasure in doing things) at Day 43 is reported. The PHQ-9 is a 9-item, participant reported outcome measure to assess depressive symptoms. The scale scores each of the 9 symptom domains of the Diagnostic and Statistical Manual of Mental Disorders-5th Edition (DSM-5) MDD criteria. Each item is rated on a 4 point scale (0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day). The participant's item responses are summed to provide a total score (range of 0 to 27), with higher scores indicating greater severity of depressive symptoms. The severity of the PHQ-9 is categorized as follows: none-minimal (0-4), mild (5-9), moderate (10-14), moderately severe (15-19) and severe (20-27).

Time frame:
At Day 43
Reported as:
Number · Percentage of participants
Percentage of Participants With a Score Less Than (<) 2 in the PHQ-9 Anhedonia-specific Item (PHQ-9, Item 1) at Day 43
Percentage of participantsPlaceboAticaprant 10 mg
Percentage of Participants With a Score Less Than (<) 2 in the PHQ-9 Anhedonia-specific Item (PHQ-9, Item 1) at Day 4341.252.3
SecondaryChange From Baseline Over Time in Patient Reported Outcomes Measurement Information System Short Form - Ability to Participate in Social Roles and Activities - 8a (PROMIS-APS 8a)

Change from baseline over time in the PROMIS-APS 8a is reported. This 8-item measure assesses participants' ability to participate in social roles and activities. The items measures the degree of involvement in social roles, activities, and responsibilities, including work, family, friends, and leisure. Each item is rated on a 5-point ordinal scale including 1=always, 2=usually, 3=sometimes, 4=rarely and 5=never, with higher scores indicating better social functioning. The total scores of PROMIS-APS 8a ranges from 8 to 40 and is transformed using a T-score metric with a mean of 50 and a standard deviation of 10. T-score ranges from 25.9 to 65.4, a higher score indicates better social functioning. Positive change in score indicates improvement.

Time frame:
Baseline (Day 1), Days 15, 29, and 43
Reported as:
Least squares mean · T-score
Change From Baseline Over Time in Patient Reported Outcomes Measurement Information System Short Form - Ability to Participate in Social Roles and Activities - 8a (PROMIS-APS 8a)
T-scorePlaceboAticaprant 10 mg
At Day 152.3 ± 0.482.6 ± 0.46
At Day 292.8 ± 0.543.9 ± 0.52
At Day 434.3 ± 0.635.5 ± 0.61
SecondaryPercent Change From Baseline Over Time in Work Productivity and Activity Impairment: Depression (WPAI:D)

The WPAI:D questionnaire is a validated short instrument that assesses impairment in work and other regular activities over the past 7 days. The WPAI yields four types of scores: (a) Absenteeism (work time missed); (b) Presenteeism (impairment at work / reduced on-the-job effectiveness); (c) Work productivity loss (overall work impairment / absenteeism plus presenteeism); (d) Activity Impairment. The first three scores are derived only for respondents who were working (should be missing for non-working), but the last score is applicable for all respondents. Each score ranges from 0 to 100 with higher scores indicating greater impairment and less productivity. Negative changes in score indicates less impairment and greater productivity.

Time frame:
Baseline (Day 1), Days 29 and 43
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline Over Time in Work Productivity and Activity Impairment: Depression (WPAI:D)
Percent ChangePlaceboAticaprant 10 mg
Overall work impairment: Day 29-5.8 ± 4.59-14.2 ± 4.71
Overall work impairment: Day 43-13.9 ± 5.07-12.9 ± 5.09
Activity impairment: Day29-9.2 ± 2.12-13.9 ± 2.03
Activity impairment: Day43-13.9 ± 2.28-18.1 ± 2.20
SecondaryDB Treatment Phase: Percentage of Participants With Treatment Emergent Adverse Events (TEAEs)

Percentage of participants with TEAEs during DB treatment phase are reported. A TEAE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. A TEAE does not necessarily have a causal relationship with the intervention. TEAEs included both serious and non serious adverse events. TEAEs were defined as AEs with onset during the DB Treatment Phase, or AEs that are a consequence of a pre-existing condition that has worsened since baseline (Day 1).

Time frame:
From start of treatment (Day 1) up to Day 43
Reported as:
Number · Percentage of participants
DB Treatment Phase: Percentage of Participants With Treatment Emergent Adverse Events (TEAEs)
Percentage of participantsDB: PlaceboDB: Aticaprant 10 mg
DB Treatment Phase: Percentage of Participants With Treatment Emergent Adverse Events (TEAEs)39.545.8
SecondaryFollow-up (FU) Phase: Percentage of Participants With AEs

An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention.

Time frame:
From Day 44 up to Day 57
Reported as:
Number · Percentage of participants
Follow-up (FU) Phase: Percentage of Participants With AEs
Percentage of participantsFU: PlaceboFU: Aticaprant 10 mg
Follow-up (FU) Phase: Percentage of Participants With AEs8.37.1

Adverse events

Collected over DB treatment phase: start of treatment (Day 1) up to Day 43, FU Phase: From Day 44 up to Day 57. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DB: Placebo0/258 (0%)1/258 (0.4%)34/258 (13.2%)
DB: Aticaprant 10 mg0/253 (0%)3/253 (1.2%)54/253 (21.3%)
FU: Placebo0/24 (0%)0/24 (0%)0/24 (0%)
FU: Aticaprant0/14 (0%)0/14 (0%)1/14 (7.1%)
Most frequent serious events
Most frequent serious events
EventDB: PlaceboDB: Aticaprant 10 mgFU: PlaceboFU: Aticaprant
Pancreatitis AcuteGastrointestinal disorders0/2581/2530/240/14
Suicidal BehaviourPsychiatric disorders0/2581/2530/240/14
AsthmaRespiratory, thoracic and mediastinal disorders0/2581/2530/240/14
PneumoniaInfections and infestations1/2580/2530/240/14
Most frequent other events
Most frequent other events
EventDB: PlaceboDB: Aticaprant 10 mgFU: PlaceboFU: Aticaprant
PruritusSkin and subcutaneous tissue disorders6/25831/2530/240/14
HeadacheNervous system disorders22/25817/2530/240/14
NasopharyngitisInfections and infestations6/2584/2530/241/14
DiarrhoeaGastrointestinal disorders8/25814/2530/240/14

Baseline characteristics

Safety analysis set included all randomized participants (adults and elderly) who took at least 1 dose of study intervention.

Age, Continuous
Age, Continuous(Years)PlaceboAticaprant 10 mgTotal
Mean51.4 ± 13.350.2 ± 14.650.8 ± 13.73
Age, Customized
Age, Customized(Participants)PlaceboAticaprant 10 mgTotal
<18 years000
Between 18 and 64 years213212425
Between 65 to 74 years454186
Sex/Gender, Customized
Sex/Gender, Customized(Participants)PlaceboAticaprant 10 mgTotal
Female185184369
Male7269141
Undifferentiated101
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboAticaprant 10 mgTotal
Hispanic or Latino7371144
Not Hispanic or Latino179176355
Unknown or Not Reported6612
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboAticaprant 10 mgTotal
American Indian or Alaska Native101
Asian145
Native Hawaiian or Other Pacific Islander538
Black or African American252449
White222213435
More than one race112
Missing or Not reported3811
Region of Enrollment
Region of Enrollment(Participants)PlaceboAticaprant 10 mgTotal
Argentina181634
Australia6713
Belgium121224
Brazil231841
Bulgaria171633
Czech Republic201838
Hungary246
Italy213
Poland141731
Portugal235
Spain7916
Sweden191837
United States116114230
08

Study locations

120 sites
  • SW Biomedical Research LLC
    Tucson, Arizona 85712, United States
  • University of Arizona
    Tucson, Arizona 85713, United States
  • Advanced Research Center Inc
    Anaheim, California 92805, United States
  • Proscience Research Group
    Culver City, California 90230, United States
  • Behavioral Research Specialists LLC
    Glendale, California 91206, United States
  • Asclepes Research
    Long Beach, California 90807, United States
  • Excell Research Inc
    Oceanside, California 92056, United States
  • Syrentis Clinical Research
    Santa Ana, California 92705, United States
  • Viking Clinical Research Ltd
    Temecula, California 92591, United States
  • University of Connecticut Health Center
    Farmington, Connecticut 06030, United States
  • Innovative Research of West Florida, Incorporated
    Clearwater, Florida 33756, United States
  • Vertex Research Group, Inc
    Clermont, Florida 34711, United States
  • Gulfcoast Medical Research Center
    Fort Myers, Florida 33912, United States
  • New Life Medical Research Center, Inc.
    Hialeah, Florida 33012, United States
  • Amedica Research Institute Inc
    Hialeah, Florida 33013, United States
  • Convenient Medical Center
    Hialeah, Florida 33013, United States
  • Galiz Research
    Hialeah, Florida 33016, United States
  • Pharmax Research Clinic Inc
    Miami, Florida 33126, United States
  • A Plus Research
    Miami, Florida 33144, United States
  • Meridian International Research
    Miami Gardens, Florida 33014, United States
  • University of Miami
    Miami Lakes, Florida 33016, United States
  • Medical Research Group of Central Florida
    Orange City, Florida 32763, United States
  • USF, Department of Psychiatry and Behavioral Neurosciences
    Tampa, Florida 33613, United States
  • Research Network America
    Berwyn, Illinois 60402, United States
  • Chicago Research Center
    Chicago, Illinois 60634, United States
  • University of Kansas Medical Center Research Institute
    Kansas City, Kansas 66160, United States
  • Clinical Trials of America
    Monroe, Louisiana 71203, United States
  • ActivMed Practices and Research
    Methuen, Massachusetts 01844, United States
  • Psychiatric Care and Research Center (PCRC)
    O'Fallon, Missouri 63368, United States
  • Bioscience Research LLC
    Mount Kisco, New York 10549, United States
  • Fieve Clinical Research Inc
    New York, New York 10168, United States
  • Finger Lakes Clinical Research
    Rochester, New York 14618, United States
  • Montefiore Medical Center PRIME
    The Bronx, New York 10467, United States
  • Patient Priority Clinical Sites LLC
    Cincinnati, Ohio 45215, United States
  • University of Cincinnati Medical Center
    Cincinnati, Ohio 45219, United States
  • Midwest Clinical Research Center
    Dayton, Ohio 45417, United States
  • Charak Center for Health and Wellness
    Garfield Heights, Ohio 44125, United States
  • Suburban Research Associates
    Media, Pennsylvania 19063, United States
  • University of Pennsylvania - Perelman School of Medicine
    Philadelphia, Pennsylvania 19104, United States
  • West Houston Clinical Research Service
    Bellaire, Texas 77401, United States
  • North Texas Clinical Trials
    Fort Worth, Texas 76104, United States
  • Bay Area Clinical Services
    Friendswood, Texas 77546, United States
  • Clinical Trial Network - Houston
    Houston, Texas 77074, United States
  • Alpine Research Organization
    Clinton, Utah 84015, United States
  • University of Virginia
    Charlottesville, Virginia 22903, United States
  • Northwest Clinical Research Center
    Bellevue, Washington 98007, United States
  • Hospital Italiano
    Buenos Aires, 1199, Argentina
  • STAT Research S A
    Buenos Aires, C1013AAB, Argentina
  • CIPREC
    Buenos Aires, C1061AAS, Argentina
  • CENydET - Centro Neurobiologico y de Stress Traumatico
    Ciudad Autonoma Buenos Aires, 1058 AAJ, Argentina
  • Fundacion Lennox
    Córdoba, 5000, Argentina
  • CENPIA
    La Plata, 1902, Argentina
  • Resolution
    Mendoza, M5502AHV, Argentina
  • Instituto Medico de La Fundacion Estudios Clinicos
    Rosario, S2000DEJ, Argentina
  • Peninsula Therapeutic & Research Group
    Frankston, 3199, Australia
  • Albert Road Clinic
    Melbourne, 3004, Australia
  • The Alfred Hospital
    Melbourne, 3004, Australia
  • Anima
    Alken, 3570, Belgium
  • C.H.U. Brugmann
    Brussels, 1020, Belgium
  • Pz Duffel
    Duffel, 2570, Belgium
  • Vitaz
    Sint-Niklaas, 9100, Belgium
  • Universidade Federal do Ceara Hospital Universitario Walter Cantidio
    Fortaleza, 60430-370, Brazil
  • Instituto Goiano de Neuropsiquiatria
    Goiânia, 74093 040, Brazil
  • NPCRS Nucleo de Pesquisa Clinica do Rio Grande do Sul
    Porto Alegre, 90430001, Brazil
  • Ruschel Medicina e Pesquisa Clínica Ltda
    Rio de Janeiro, 22270 060, Brazil
  • CEMEC - Centro Multidisciplinar de Estudos Clínicos
    São Bernardo do Campo, 09715-090, Brazil
  • Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto Hospital de Base
    São José do Rio Preto, 15090-000, Brazil
  • CPQuali Pesquisa Clinica LTDA ME
    São Paulo, 01228-900, Brazil
  • BR Trials
    São Paulo, 05003 020, Brazil
  • Ambulatory for Individual Practice for Specialized Medical Care in Psychiatry Dr. Ivo Natsov ET
    Cherven Bryag, 5980, Bulgaria
  • Ambulatory Group practice for specialized help in psychiary Philipopolis ODD
    Plovdiv, 4002, Bulgaria
  • Medical Center Mentalcare OOD
    Plovdiv, 4004, Bulgaria
  • Mental Health Center - Rousse
    Rousse, 7003, Bulgaria
  • Medical Center St. Naum
    Sofia, 1113, Bulgaria
  • Mental Health Center - Veliko Tarnovo EOOD
    Veliko Tarnovo, 5000, Bulgaria
  • Narodni ustav dusevniho zdravi
    Klecany, 25067, Czechia
  • A Shine S R O
    Pilsen, 301 00, Czechia
  • Clintrial s r o
    Prague, 100 00, Czechia
  • AD71 s.r.o.
    Prague, 109 00, Czechia
  • Praglandia s r o
    Prague, 15000, Czechia
  • NeuropsychiatrieHK, s.r.o.
    Prague, 160 00, Czechia
  • Psychiatricka ordinace
    Ústí nad Labem, 400 01, Czechia
  • Obudai Egeszsegugyi Centrum Kft
    Budapest, 1036, Hungary
  • Semmelweis Egyetem
    Budapest, 1083, Hungary
  • Nyiro Gyula Korhaz
    Budapest, 1135, Hungary
  • Bugat Pal Korhaz
    Gyöngyös, 3200, Hungary
  • Dr Mathe es Tarsa Bt
    Kalocsa, 6300, Hungary
  • PsychoTech Kft
    Pécs, 7633, Hungary
  • Tolna Megyei Balassa Janos Korhaz
    Szekszárd, 7100, Hungary
  • Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni XXIII)
    Bergamo, 24127, Italy
  • Azienda Ospedaliero Universitaria Mater Domini
    Catanzaro, 88100, Italy
  • AUSL LE di Lecce
    Lecce, 73100, Italy
  • Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico
    Milan, 20122, Italy
  • ASST Fatebenefratelli Sacco
    Milan, 20157, Italy
  • Ospedale San Raffaele
    Milan, Italy
  • Azienda Ospedaliera Universitaria Senese Policlinico Santa Maria alle Scotte
    Siena, 53100, Italy
  • Gabinet Lekarski Psychiatryczny Ireneusz Kaczorowski
    Bełchatów, 97-400, Poland
  • Mlynowamed Specjalistyczny Psychiatryczny Gabinet Lekarski Joanna Lazarczyk
    Bialystok, 15-404, Poland
  • Centrum Badan Klinicznych PI House sp z o o
    Gdansk, 80 546, Poland
  • Specjalistyczna Indywidualna Praktyka Lekarska
    Lodz, 90-009, Poland

Showing the first 100 of 120 sites across 13 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · www.janssen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2022 to primary completion in Sep 2024, 26 months.

Results were first posted in Nov 2025, 1 year 1 month after primary completion.

Of 95 industry-sponsored phase 3 interventional studies under Depressive Disorder, Major, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's 26 months is close to that.

Counting every sponsor, half of 124 studies reached it within 27 months; a quarter within 21 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2022
First posted
Jul 13, 2022
StartActual
Jun 22, 2022
Primary completionActual
Sep 18, 2024
CompletionActual
Sep 18, 2024
Results first posted
Nov 6, 2025
Last update
Nov 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05455684
Responsible party
Sponsor
First posted
Jul 13, 2022
Start date
Jun 22, 2022
Primary completion
Sep 18, 2024
Completion
Sep 18, 2024
Results posted
Nov 6, 2025
Last update
Nov 6, 2025

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aticaprant

Start the discussion